These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 25961497

  • 1. Simultaneously Targeting the NS3 Protease and Helicase Activities for More Effective Hepatitis C Virus Therapy.
    Ndjomou J, Corby MJ, Sweeney NL, Hanson AM, Aydin C, Ali A, Schiffer CA, Li K, Frankowski KJ, Schoenen FJ, Frick DN.
    ACS Chem Biol; 2015 Aug 21; 10(8):1887-96. PubMed ID: 25961497
    [Abstract] [Full Text] [Related]

  • 2. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.
    McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.
    J Virol; 2015 May 21; 89(10):5362-70. PubMed ID: 25740995
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.
    Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC.
    Antimicrob Agents Chemother; 2017 Jul 21; 61(7):. PubMed ID: 28416549
    [Abstract] [Full Text] [Related]

  • 5. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J.
    Gastroenterology; 2014 Mar 21; 146(3):812-821.e4. PubMed ID: 24262279
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease.
    Welsch C, Shimakami T, Hartmann C, Yang Y, Domingues FS, Lengauer T, Zeuzem S, Lemon SM.
    Gastroenterology; 2012 Mar 21; 142(3):654-63. PubMed ID: 22155364
    [Abstract] [Full Text] [Related]

  • 10. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.
    Mukherjee S, Weiner WS, Schroeder CE, Simpson DS, Hanson AM, Sweeney NL, Marvin RK, Ndjomou J, Kolli R, Isailovic D, Schoenen FJ, Frick DN.
    ACS Chem Biol; 2014 Oct 17; 9(10):2393-403. PubMed ID: 25126694
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection.
    Deutsch M, Papatheodoridis GV.
    Curr Opin Investig Drugs; 2010 Aug 17; 11(8):951-63. PubMed ID: 20721837
    [Abstract] [Full Text] [Related]

  • 13. Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba.
    Andonov A, Kadkhoda K, Osiowy C, Kaita K.
    Can J Gastroenterol; 2013 Jul 17; 27(7):414-6. PubMed ID: 23862174
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations.
    Aloia AL, Eyre NS, Black S, Bent SJ, Gaeguta A, Guo Z, Narayana SK, Chase R, Locarnini S, Carr JM, Howe JA, Beard MR.
    Antivir Ther; 2015 Jul 17; 20(3):271-80. PubMed ID: 25222708
    [Abstract] [Full Text] [Related]

  • 18. Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants.
    Doncheva NT, Domingues FS, McGivern DR, Shimakami T, Zeuzem S, Lengauer T, Lange CM, Albrecht M, Welsch C.
    J Mol Biol; 2019 May 31; 431(12):2354-2368. PubMed ID: 31051172
    [Abstract] [Full Text] [Related]

  • 19. Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.
    Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM.
    Antimicrob Agents Chemother; 2016 Jun 31; 60(6):3563-78. PubMed ID: 27021330
    [Abstract] [Full Text] [Related]

  • 20. Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
    López-Labrador FX, Moya A, Gonzàlez-Candelas F.
    Antivir Ther; 2008 Jun 31; 13(4):481-94. PubMed ID: 18672527
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.